Recent Updates
Recently added Catalysts

H-coil dTMS

Phase 2

Major Depressive Disorder | Unknown | Psychiatry |BrainsWay Ltd.|Last Updated: Jan 5, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment29
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00807105Evaluation of the H-coil Transcranial Magnetic Stimulation TMS Device - Safety and Feasibility Study for Acute and Maintenance Treatment in Major Depressive EpisodePHASE2 COMPLETED 29 — — Jun 1, 2008May 1, 2010Jan 5, 20121 Israel
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
response in HAMDS
1 YEAR
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
depressive patientsEXPERIMENTALpatients suffering from deppresion
Interventions
NameTypeDescription
H-coil dTMSDEVICEtreatment with deep TMS stimulation.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * MDD patients Exclusion Criteria: * risk factors for convulsions

Countries:Israel
Unlock Eligibility Criteria
Competitive Landscape -Major Depressive Disorder 91 trials
CompanyTickerTrialsLead PhaseDrugs
COMPASS Pathways Plc Sponsored ADRCMPS5PHASE3Psilocybin
Neurocrine Biosciences, Inc.NBIX5PHASE3NBI-1065845
Johnson & JohnsonJNJ4PHASE3Esketamine, Midazolam, Seltorexant, Selective Serotonin Reuptake Inhibitor /Serotonin-Norepinephrine Reuptake Inhibitor, JNJ-89495120
AbbVie, Inc.ABBV2PHASE3Cariprazine, Icalcaprant
Xenon Pharmaceuticals Inc.XENE3PHASE3Azetukalner
Axsome Therapeutics, Inc.AXSM2PHASE3Solriamfetol, Dextromethorphan-Bupropion
Neumora Therapeutics, Inc.NMRA3PHASE3NMRA-335140
Definium Therapeutics, Inc.DFTX2PHASE3MM120, DT120
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3Vortioxetine
Eli Lilly and CompanyLLY1PHASE3Brenipatide
Cybin, Inc.HELP3PHASE3CYB003
Vanda Pharmaceuticals Inc.VNDA1PHASE3Milsaperidone
AtaiBeckley Inc.ATAI3PHASE2VLS-01-203 BU, BPL-003, ELE-101
ACADIA Pharmaceuticals Inc.ACAD1PHASE2ACP-211
Supernus Pharmaceuticals, Inc.SUPN1PHASE2SPN-821
Alto Neuroscience, Inc.ANRO1PHASE2ALTO-300
Harvard Bioscience, Inc.HBIO2PHASE3Antidepressant medication
Seaport Therapeutics, Inc.SPTX2PHASE2SPT-300
Masimo CorporationMASI1PHASE1Diprivan , Astra-Zeneca
Abbott LaboratoriesABT1NAUndisclosed
Unlock Competitive Intelligence